Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 3130496, 16 pages
http://dx.doi.org/10.1155/2016/3130496
Review Article

Characterization and Functions of Protease-Activated Receptor 2 in Obesity, Diabetes, and Metabolic Syndrome: A Systematic Review

1Department of Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, Nishinomiya, Hyogo 6638179, Japan
2Cardiovascular Research Group, Division of BioMedical Sciences, Faculty of Medicine, Memorial University, St. John’s, Newfoundland and Labrador, Canada A1B 3V6

Received 20 October 2015; Accepted 26 January 2016

Academic Editor: Andrea Mencarelli

Copyright © 2016 Satomi Kagota et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Dandona, A. Aljada, A. Chaudhuri, P. Mohanty, and R. Garg, “Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation,” Circulation, vol. 111, no. 11, pp. 1448–1454, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. P. M. Vanhoutte, “Endothelial dysfunction in hypertension,” Journal of Hypertension, Supplement, vol. 14, no. 5, pp. S83–S93, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Nystedt, K. Emilsson, A.-K. Larsson, B. Strombeck, and J. Sundelin, “Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2,” European Journal of Biochemistry, vol. 232, no. 1, pp. 84–89, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Nystedt, A.-K. Larsson, H. Åberg, and J. Sundelin, “The mouse proteinase-activated receptor-2 cDNA and gene. Molecular cloning and functional expression,” The Journal of Biological Chemistry, vol. 270, no. 11, pp. 5950–5955, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Samad and W. Ruf, “Inflammation, obesity, and thrombosis,” Blood, vol. 122, no. 20, pp. 3415–3422, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. D. Hollenberg and J. Trejo, Proteinase-Activated Receptors: PAR2, IUPHAR/BPS Guide to Pharmacology, 2015.
  7. M. Saifeddine, B. Al Ani, C.-H. Cheng, L. Wang, and M. D. Hollenberg, “Rat proteinase-activated receptor-2 (PAR-2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue,” British Journal of Pharmacology, vol. 118, no. 3, pp. 521–530, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Syeda, J. Grosjean, R. A. Houliston et al., “Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-κB pathways,” The Journal of Biological Chemistry, vol. 281, no. 17, pp. 11792–11804, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Bono, I. Lamarche, and J. M. Herbert, “Induction of vascular smooth muscle cell growth by selective activation of the proteinase activated receptor-2 (PAR-2),” Biochemical and Biophysical Research Communications, vol. 241, no. 3, pp. 762–764, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. J. C. Hennessey, B. D. Stuyvers, and J. J. McGuire, “Small caliber arterial endothelial cells calcium signals elicited by PAR2 are preserved from endothelial dysfunction,” Pharmacology Research & Perspectives, vol. 3, no. 2, Article ID e00112, 2015. View at Publisher · View at Google Scholar
  11. R. Ramachandran, F. Noorbakhsh, K. Defea, and M. D. Hollenberg, “Targeting proteinase-activated receptors: therapeutic potential and challenges,” Nature Reviews Drug Discovery, vol. 11, no. 1, pp. 69–86, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. K. A. DeFea, J. Zalevsky, M. S. Thoma, O. Dery, R. D. Mullins, and N. W. Bunnett, “β-Arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2,” Journal of Cell Biology, vol. 148, no. 6, pp. 1267–1281, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Saifeddine, M. El-Daly, K. Mihara et al., “GPCR-mediated EGF receptor transactivation regulates TRPV4 action in the vasculature,” British Journal of Pharmacology, vol. 172, no. 10, pp. 2493–2506, 2015. View at Publisher · View at Google Scholar
  14. J.-S. Joyal, S. Nim, T. Zhu et al., “Subcellular localization of coagulation factor II receptor-like 1 in neurons governs angiogenesis,” Nature Medicine, vol. 20, no. 10, pp. 1165–1173, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Mihara, R. Ramachandran, B. Renaux, M. Saifeddine, and M. D. Hollenberg, “Neutrophil elastase and proteinase-3 trigger G protein-biased signaling through proteinase-activated receptor-1 (PAR1),” The Journal of Biological Chemistry, vol. 288, no. 46, pp. 32979–32990, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. M. D. Hollenberg, K. Mihara, D. Polley et al., “Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease,” British Journal of Pharmacology, vol. 171, no. 5, pp. 1180–1194, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. T. Fox, P. Harriott, B. Walker, and S. R. Stone, “Identification of potential activators of proteinase-activated receptor-2,” FEBS Letters, vol. 417, no. 3, pp. 267–269, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Molino, E. S. Barnathan, R. Numerof et al., “Interactions of mast cell tryptase with thrombin receptors and PAR-2,” The Journal of Biological Chemistry, vol. 272, no. 7, pp. 4043–4049, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Seitz, S. Hess, H. Schulz et al., “Membrane-type serine protease-1/matriptase induces interleukin-6 and -8 in endothelial cells by activation of protease-activated receptor-2: potential implications in atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 4, pp. 769–775, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Ramachandran, A. Eissa, K. Mihara et al., “Proteinase-activated receptors (PARs): differential signalling by kallikrein-related peptidases KLK8 and KLK14,” Biological Chemistry, vol. 393, no. 5, pp. 421–427, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. D. J. Lerner, M. Chen, T. Tram, and S. R. Coughlin, “Agonist recognition by proteinase-activated receptor 2 and thrombin receptor: importance of extracellular loop interactions for receptor function,” The Journal of Biological Chemistry, vol. 271, no. 24, pp. 13943–13947, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. S. B. Elmariah, V. B. Reddy, and E. A. Lerner, “Cathepsin S signals via PAR2 and generates a novel tethered ligand receptor agonist,” PLoS ONE, vol. 9, no. 6, Article ID e99702, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Ramachandran, K. Mihara, H. Chung et al., “Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2),” The Journal of Biological Chemistry, vol. 286, no. 28, pp. 24638–24648, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M.-K. Yau, L. Liu, and D. P. Fairlie, “Toward drugs for protease-activated receptor 2 (PAR2),” Journal of Medicinal Chemistry, vol. 56, no. 19, pp. 7477–7497, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Al-Ani, M. Saifeddine, and M. D. Hollenberg, “Detection of functional receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-NH2, in rat vascular and gastric smooth muscle,” Canadian Journal of Physiology and Pharmacology, vol. 73, no. 8, pp. 1203–1207, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. M. D. Hollenberg, M. Saifeddine, and B. Al-Ani, “Proteinase-activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides,” Molecular Pharmacology, vol. 49, no. 2, pp. 229–233, 1996. View at Google Scholar · View at Scopus
  27. M. D. Hollenberg, M. Saifeddine, B. Al-Ani, and A. Kawabata, “Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides,” Canadian Journal of Physiology and Pharmacology, vol. 75, no. 7, pp. 832–841, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. J. J. McGuire, M. Saifeddine, C. R. Triggle, K. Sun, and M. D. Hollenberg, “2-Furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist,” Journal of Pharmacology and Experimental Therapeutics, vol. 309, no. 3, pp. 1124–1131, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. G. D. Barry, J. Y. Suen, G. T. Le, A. Cotterell, R. C. Reid, and D. P. Fairlie, “Novel agonists and antagonists for human protease activated receptor 2,” Journal of Medicinal Chemistry, vol. 53, no. 20, pp. 7428–7440, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. J. G. Seitzberg, A. E. Knapp, B. W. Lund et al., “Discovery of potent and selective small-molecule PAR-2 agonists,” Journal of Medicinal Chemistry, vol. 51, no. 18, pp. 5490–5493, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Boitano, J. Hoffman, D. V. Tillu et al., “Development and evaluation of small peptidomimetic ligands to protease-activated receptor-2 (PAR2) through the use of lipid tethering,” PLoS ONE, vol. 9, no. 6, Article ID e99140, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. A. N. Flynn, D. V. Tillu, M. N. Asiedu et al., “The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl- LIGRL-NH2and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo,” The Journal of Biological Chemistry, vol. 286, no. 21, pp. 19076–19088, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Y. Suen, G. D. Barry, R. J. Lohman et al., “Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110),” British Journal of Pharmacology, vol. 165, no. 5, pp. 1413–1423, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Boitano, J. Hoffman, A. N. Flynn et al., “The novel PAR2 ligand C391 blocks multiple PAR2 signalling pathways in vitro and in vivo,” British Journal of Pharmacology, vol. 172, no. 18, pp. 4535–4545, 2015. View at Publisher · View at Google Scholar
  35. L. M. Sevigny, P. Zhang, A. Bohm et al., “Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 20, pp. 8491–8496, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Crilly, H. Palmer, M. B. Nickdel et al., “Immunomodulatory role of proteinase-activated receptor-2,” Annals of the Rheumatic Diseases, vol. 71, no. 9, pp. 1559–1566, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Hoffman, A. N. Flynn, D. V. Tillu et al., “Lanthanide labeling of a potent protease activated receptor-2 agonist for time-resolved fluorescence analysis,” Bioconjugate Chemistry, vol. 23, no. 10, pp. 2098–2104, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. M. D. Hollenberg, B. Renaux, E. Hyun et al., “Derivatized 2-furoyl-LIGRLO-amide, a versatile and selective probe for proteinase-activated receptor 2: Binding and visualization,” Journal of Pharmacology and Experimental Therapeutics, vol. 326, no. 2, pp. 453–462, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. E. B. Kelso, J. C. Lockhart, T. Hembrough et al., “Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation,” Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 3, pp. 1017–1024, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. R.-J. Lohman, A. J. Cotterell, J. Suen et al., “Antagonism of protease-activated receptor 2 protects against experimental colitis,” Journal of Pharmacology and Experimental Therapeutics, vol. 340, no. 2, pp. 256–265, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Y. Suen, A. Cotterell, R. J. Lohman et al., “Pathway-selective antagonism of proteinase activated receptor 2,” British Journal of Pharmacology, vol. 171, no. 17, pp. 4112–4124, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. K. O'Callaghan, A. Kuliopulos, and L. Covic, “Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development,” The Journal of Biological Chemistry, vol. 287, no. 16, pp. 12787–12796, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. J. J. McGuire, M. D. Hollenberg, P. Andrade-Gordon, and C. R. Triggle, “Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles,” British Journal of Pharmacology, vol. 135, no. 1, pp. 155–169, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. J. J. McGuire, “Proteinase-activated Receptor 2 (PAR2): a challenging new target for treatment of vascular diseases,” Current Pharmaceutical Design, vol. 10, no. 22, pp. 2769–2778, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. G. M. Tennant, R. M. Wadsworth, and S. Kennedy, “PAR-2 mediates increased inflammatory cell adhesion and neointima formation following vascular injury in the mouse,” Atherosclerosis, vol. 198, no. 1, pp. 57–64, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Roviezzo, M. Bucci, V. Brancaleone et al., “Proteinase-activated receptor-2 mediates arterial vasodilation in diabetes,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 11, pp. 2349–2354, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Matsumoto, K. Ishida, K. Taguchi, T. Kobayashi, and K. Kamata, “Mechanisms underlying enhanced vasorelaxant response to protease-activated receptor 2-activating peptide in type 2 diabetic Goto-Kakizaki rat mesenteric artery,” Peptides, vol. 30, no. 9, pp. 1729–1734, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Li, K. Mihara, M. Saifeddine et al., “Perivascular adipose tissue-derived relaxing factors: release by peptide agonists via proteinase-activated receptor-2 (PAR2) and non-PAR2 mechanisms,” British Journal of Pharmacology, vol. 164, no. 8, pp. 1990–2002, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. Z. J. Cheng, Y.-F. Jiang, H. Ding, D. Severson, and C. R. Triggle, “Vascular dysfunction in type 2 diabetic TallyHo mice: role for an increase in the contribution of PGH2/TxA2 receptor activation and cytochrome p450 products,” Canadian Journal of Physiology and Pharmacology, vol. 85, no. 3-4, pp. 404–412, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Park, J. Yang, H. Zhang, X. Chen, and C. Zhang, “Effect of PAR2 in regulating TNF-α and NAD(P)H oxidase in coronary arterioles in type 2 diabetic mice,” Basic Research in Cardiology, vol. 106, no. 1, pp. 111–123, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Kagota, E. Chia, and J. J. McGuire, “Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diabetic mice,” British Journal of Pharmacology, vol. 164, no. 2, pp. 358–371, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Kagota, K. Maruyama, H. Wakuda et al., “Disturbance of vasodilation via protease-activated receptor 2 in SHRSP.Z-Leprfa/IzmDmcr rats with metabolic syndrome,” Vascular Pharmacology, vol. 63, no. 1, pp. 46–54, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Howitt, M. J. Morris, S. L. Sandow, and T. V. Murphy, “Effect of diet-induced obesity on BK(Ca) function in contraction and dilation of rat isolated middle cerebral artery,” Vascular Pharmacology, vol. 61, no. 1, pp. 10–15, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Wei, E. Geras-Raaka, B. Marcus-Samuels, Y. Oron, and M. C. Gershengorn, “Trypsin and thrombin accelerate aggregation of human endocrine pancreas precursor cells,” Journal of Cellular Physiology, vol. 206, no. 2, pp. 322–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Hyun, R. Ramachandran, N. Cenac et al., “Insulin modulates protease-activated receptor 2 signaling: implications for the innate immune response,” Journal of Immunology, vol. 184, no. 5, pp. 2702–2709, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Wang, Y. Jiang, Y. Wang, J. Y. Shyy, and K. A. DeFea, “Beta-arrestin inhibits CAMKKbeta-dependent AMPK activation downstream of protease-activated-receptor-2,” BMC Biochemistry, vol. 11, article 36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Badeanlou, C. Furlan-Freguia, G. Yang, W. Ruf, and F. Samad, “Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation,” Nature Medicine, vol. 17, no. 11, pp. 1490–1497, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Borrelli, R. Capasso, B. Severino et al., “Inhibitory effects of bromelain, a cysteine protease derived from pineapple stem (Ananas comosus), on intestinal motility in mice,” Neurogastroenterology and Motility, vol. 23, no. 8, p. 745-e331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Sumi, N. Yamanaka-Hanada, F. Bai, T. Makino, H. Mizukami, and T. Ono, “Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice,” Biological and Pharmaceutical Bulletin, vol. 34, no. 6, pp. 824–830, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. J. G. Rasmussen, S. E. Riis, O. Frøbert et al., “Activation of protease-activated receptor 2 induces VEGF independently of HIF-1,” PLoS ONE, vol. 7, no. 9, Article ID e46087, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Pilgaard, P. Lund, T. Fink, and V. Zachar, “Comparative analysis of highly defined proteases for the isolation of adipose tissue-derived stem cells,” Regenerative Medicine, vol. 3, no. 5, pp. 705–715, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. P. B. Shetty, H. Tang, B. O. Tayo et al., “Variants in CXADR and F2RL1 are associated with blood pressure and obesity in African-Americans in regions identified through admixture mapping,” Journal of Hypertension, vol. 30, no. 10, pp. 1970–1976, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Lim, A. Iyer, L. Liu et al., “Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism,” The FASEB Journal, vol. 27, no. 12, pp. 4757–4767, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. S. W. Görgens, K. Eckardt, M. Elsen, N. Tennagels, and J. Eckel, “Chitinase-3-like protein 1 protects skeletal muscle from TNFα-induced inflammation and insulin resistance,” Biochemical Journal, vol. 459, no. 3, pp. 479–488, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. N. Wronkowitz, S. W. Görgens, T. Romacho et al., “Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1842, no. 9, pp. 1613–1621, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. W. H. Yiu, D. W. L. Wong, L. Y. Y. Chan et al., “Tissue kallikrein mediates pro-inflammatory pathways and activation of protease-activated receptor-4 in proximal tubular epithelial cells,” PLoS ONE, vol. 9, no. 2, Article ID e88894, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Wang, S. Chakrabarty, Q. Bui, W. Ruf, and F. Samad, “Hematopoietic tissue factor-protease-activated receptor 2 signaling promotes hepatic inflammation and contributes to pathways of gluconeogenesis and steatosis in obese mice,” The American Journal of Pathology, vol. 185, no. 2, pp. 524–535, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Nystedt, V. Ramakrishnan, and J. Sundelin, “The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor,” The Journal of Biological Chemistry, vol. 271, no. 25, pp. 14910–14915, 1996. View at Publisher · View at Google Scholar · View at Scopus
  69. M. N. Adams, C. N. Pagel, E. J. MacKie, and J. D. Hooper, “Evaluation of antibodies directed against human protease-activated receptor-2,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 385, no. 9, pp. 861–873, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Zhao, M. Metcalf, and N. W. Bunnett, “Biased signaling of protease-activated receptors,” Frontiers in Endocrinology, vol. 5, article 67, 2014. View at Publisher · View at Google Scholar
  71. N. Sitaras, J. C. Rivera, B. Noueihed et al., “Retinal neurons curb inflammation and enhance revascularization in ischemic retinopathies via proteinase-activated receptor-2,” American Journal of Pathology, vol. 185, no. 2, pp. 581–595, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. J. J. McGuire, B. N. Van Vliet, and S. J. Halfyard, “Blood pressures, heart rate and locomotor activity during salt loading and angiotensin II infusion in protease-activated receptor 2 (PAR2) knockout mice,” BMC Physiology, vol. 8, article 20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. J. J. McGuire, B. N. Van Vliet, J. Giménez, J. C. King, and S. J. Halfyard, “Persistence of PAR-2 vasodilation despite endothelial dysfunction in BPH/2 hypertensive mice,” Pflugers Archiv, vol. 454, no. 4, pp. 535–543, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. E. Chia, S. Kagota, E. P. Wijekoon, and J. J. McGuire, “Protection of protease-activated receptor 2 mediated vasodilatation against angiotensin II-induced vascular dysfunction in mice,” BMC Pharmacology, vol. 11, article 10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. B. Zhong and D. H. Wang, “Protease-activated receptor 2-mediated protection of myocardial ischemia-reperfusion injury: role of transient receptor potential vanilloid receptors,” American Journal of Physiology. Regulatory, integrative and Comparative Physiology, vol. 297, no. 6, pp. R1681–R1690, 2009. View at Publisher · View at Google Scholar
  76. F. Cattaruzza, N. Cenac, E. Barocelli et al., “Protective effect of proteinase-activated receptor 2 activation on motility impairment and tissue damage induced by intestinal ischemia/reperfusion in rodents,” American Journal of Pathology, vol. 169, no. 1, pp. 177–188, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. A. F. Milia, M. B. Salis, T. Stacca et al., “Protease-activated receptor-2 stimulates angiogenesis and accelerates hemodynamic recovery in a mouse model of hindlimb ischemia,” Circulation Research, vol. 91, no. 4, pp. 346–352, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. P. G. McLean, D. Aston, D. Sarkar, and A. Ahluwalia, “Protease-activated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia/reperfusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers,” Circulation Research, vol. 90, no. 4, pp. 465–472, 2002. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Napoli, F. de Nigris, C. Cicala et al., “Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 282, no. 6, pp. H2004–H2010, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. K. Oikonomopoulou, K. K. Hansen, M. Saifeddine et al., “Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs),” Biological Chemistry, vol. 387, no. 6, pp. 817–824, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. E. P. Feener, Q. Zhou, and W. Fickweiler, “Role of plasma kallikrein in diabetes and metabolism,” Thrombosis and Haemostasis, vol. 110, no. 3, pp. 434–441, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. R. T. Abdallah, J.-S. Keum, M.-H. Lee et al., “Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors,” The Journal of Biological Chemistry, vol. 285, no. 45, pp. 35206–35215, 2010. View at Publisher · View at Google Scholar
  83. J. Robin, R. Kharbanda, P. Mclean, R. Campbell, and P. Vallance, “Protease-activated receptor 2-mediated vasodilatation in humans in vivo: role of nitric oxide and prostanoids,” Circulation, vol. 107, no. 7, pp. 954–959, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. I. J. Gudmundsdóttir, I. L. Megson, J. S. Kell et al., “Direct vascular effects of protease-activated receptor type 1 agonism in vivo in humans,” Circulation, vol. 114, no. 15, pp. 1625–1632, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. A. N. Flynn, J. Hoffman, D. V. Tillu et al., “Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering,” The FASEB Journal, vol. 27, no. 4, pp. 1498–1510, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. D. V. Tillu, S. N. Hassler, C. C. Burgos-Vega et al., “Protease-activated receptor 2 activation is sufficient to induce the transition to a chronic pain state,” PAIN, vol. 156, no. 5, pp. 859–867, 2015. View at Publisher · View at Google Scholar
  87. S. G. Shimada, K. A. Shimada, and J. G. Collins, “Scratching behavior in mice induced by the proteinase-activated receptor-2 agonist, SLIGRL-NH2,” European Journal of Pharmacology, vol. 530, no. 3, pp. 281–283, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Buddenkotte, C. Stroh, I. H. Engels et al., “Agonists of proteinase-activated receptor-2 stimulate upregulation of intercellular cell adhesion molecule-1 in primary human keratinocytes via activation of NF-kappa B,” Journal of Investigative Dermatology, vol. 124, no. 1, pp. 38–45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. N. Zhang and D. A. Lawrence, “Tissue factor and obesity, a two-way street,” Nature Medicine, vol. 17, no. 11, pp. 1343–1344, 2011. View at Publisher · View at Google Scholar · View at Scopus